Suzanne Lentzsch, MD, PhD, Columbia University

Articles

Dr Lentzsch on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

October 11th 2024

Suzanne Lentzsch, MD, PhD, discusses the safety profile of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Lentzsch on Results for Linvoseltamab in Heavily Pretreated R/R Myeloma

August 7th 2024

Suzanne Lentzsch, MD, PhD discusses data for linvoseltamab in patients with relapsed/refractory multiple myeloma

Rapid Readout: Routine Clinical Practice Use of IRd in Patients With Relapsed/Refractory Multiple Myeloma (The INSURE Study)

February 24th 2022

Expert perspective on the INSURE study, which pooled data from several trials to observe the real-world effectiveness of IRd in the setting of relapsed/refractory multiple myeloma.

Dr. Lentzsch on How Patient Age Informs Treatment Decisions in Multiple Myeloma

November 12th 2021

Suzanne Lentzsch, MD, discusses how patient age informs treatment decisions in multiple myeloma.

Dr. Lentzsch on the Utility of Cellular Therapies in Multiple Myeloma

August 9th 2021

Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.

Novel Therapies Under Study for Triple-Class Refractory Multiple Myeloma

May 25th 2021

Novel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.

Addressing Unmet Needs for Triple-Class Refractory Multiple Myeloma

May 25th 2021

Current unmet needs surrounding the management of patients with triple-class refractory multiple myeloma with newer novel therapies.

Individualizing Therapy for Triple-Class Refractory Myeloma

May 25th 2021

Guidance regarding proper treatment selection and sequencing of therapies for triple-class refractory multiple myeloma.

Single-Agent Belantamab Mafodotin for Triple-Class Refractory Multiple Myeloma

May 18th 2021

An overview of the DREAMM-2 study of belantamab mafodotin for triple-class refractory patients with multiple myeloma, with special considerations for managing treatment-related corneal events.

Melflufen and Dexamethasone for Triple-Class Refractory Multiple Myeloma

May 18th 2021

The rationale for adding melflufen to dexamethasone as treatment for patients with triple-class refractory multiple myeloma.

Selinexor With Backbone Therapy for Triple-Class Refractory Multiple Myeloma

May 11th 2021

Considerations for adding selinexor to backbone treatments for triple-class refractory multiple myeloma based on data revealed by the STOMP trial.

Establishing a Treatment Plan for Triple-Class Refractory Myeloma

May 11th 2021

Insight regarding the risk of development of triple-class refractory disease in multiple myeloma and recommendations for working with patients to establish an appropriate treatment plan and counsel on goals of therapy.

Assessing and Managing Relapsed/Refractory Myeloma

May 4th 2021

Strategies for patient assessment and treatment selection in patients with relapsed/refractory multiple myeloma.

Reacting to Relapsed/Refractory Myeloma in the Clinic

May 4th 2021

Criteria for diagnosis and risk stratification in patients with relapsed/refractory multiple myeloma.